A rare case of breast squamous cell carcinoma and literature review.

Breast cancer, squamous,, metaplastic

Journal

Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 01 04 2022
revised: 15 05 2022
accepted: 16 05 2022
entrez: 23 6 2022
pubmed: 24 6 2022
medline: 24 6 2022
Statut: epublish

Résumé

Breast Squamous Cell Carcinoma (SCC) is quite a rare tumour that the features portray squamous cell differentiation. We report a case of a 56-year-old female presented left breast lump that had been increasing in size for a 7 months duration associated with nipple retraction for one week. Ultrasound breast was done and revealed a large mixed echo density mass lesion in the left breast at 12 o'clock, 2cm from the nipple and measuring 4.2 × 3.4cm along with an enlarged node in the left axilla with thickened cortex and as for Mammogram revealed suspicious left breast lesion with enlarged axillary nodes, BIRADS 5. Histopathology from the left breast showed Invasive carcinoma with squamous differentiation, B5b, ER: negative, PR: Positive, Her2: Negative, CK5/6: Positive. Then a staging CECT Thorax, Abdomen and Pelvis was done which showed enhancing mass lesion seen at the left breast (4.1 × 4.3cm) with areas of necrosis within and multiple enlarged left axillary nodes seen with no local infiltration to the muscle or skin as well as no distant metastases. Patient underwent Neoadjuvant chemotherapy for 6 cycles and completed them. This case highlights the crucial need of early detection along with the obstacles faced in reaching an early diagnosis tagged with the lack of guideline to manage this patient. In the management of Breast Squamous Cell Carcinoma, the standard treatment would be to go for mastectomy with axillary clearance. However, the prognosis usually depends on the tumour size and the advance age of the patient as described in this article.

Identifiants

pubmed: 35734729
doi: 10.1016/j.amsu.2022.103825
pii: S2049-0801(22)00585-4
pmc: PMC9206937
doi:

Types de publication

Case Reports

Langues

eng

Pagination

103825

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

All authors declare that they have no conflict of interest.

Références

Onco Targets Ther. 2016 May 27;9:3181-5
pubmed: 27313463
J Clin Oncol. 2005 Nov 1;23(31):7827-35
pubmed: 16258085
Eur J Obstet Gynecol Reprod Biol. 2008 Apr;137(2):222-6
pubmed: 17481802
Breast Cancer Res Treat. 2017 Jul;164(1):201-208
pubmed: 28432512
Int J Surg. 2020 Dec;84:226-230
pubmed: 33181358
Breast. 2000 Dec;9(6):315-9
pubmed: 14965754
Anticancer Res. 2007 Jan-Feb;27(1B):547-55
pubmed: 17348440
Eur J Surg Oncol. 2003 May;29(4):386-9
pubmed: 12711295

Auteurs

Bhirrinta Varughese (B)

Breast and Endocrine Unit, Surgery Department, Hospital Queen Elizabeth 2, Kota Kinabalu, Sabah, Malaysia.

Siti Zubaidah Sharif (SZ)

Breast and Endocrine Unit, Surgery Department, Hospital Queen Elizabeth 2, Kota Kinabalu, Sabah, Malaysia.

Ho Kah Yee (HK)

Breast and Endocrine Unit, Surgery Department, Hospital Queen Elizabeth 2, Kota Kinabalu, Sabah, Malaysia.

Nik Amin Sahid Nik Lah (NA)

Surgical Department, Faculty of Medicine & Health Sciences, University Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia.

Classifications MeSH